Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT’s Computer Science and Artificial Intelligence Laboratory. His healthcare-related research interests include: new financial engineering tools and business models for drug and device development and healthcare delivery; statistical methods for incorporating patient preferences into the drug approval process; predicting clinical trial outcomes via machine learning techniques; and novel funding and reimbursement models for creating a robust gene therapy ecosystem. He is a co-founder and director of BridgeBio Pharma, a director of Atomwise and Roivant Sciences, a co-founder and chairman of QLS Advisors, and a member of the advisory boards of NCATS and the American Cancer Society’s BrightEdge Impact Fund. Dr. Lo received his B.A. in economics from Yale University and his A.M. and Ph.D. in economics from Harvard University.
Andrew Lo, Ph.D.